CClinicalTrials.gg
RecruitingNCT07414901Updated Jul 9, 2026

Group Postpartum and Well-Child Care for Maternal and Infant Health

An interventional study of Group Care in Postpartum Health and Infant Health, sponsored by Johns Hopkins University. Recruiting at 16 sites in Malawi. Open to participants aged 1 Week to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
1,125
Allocation
Randomized
Ages
1 Week to 75 Years
Sex
All
01

Study summary

The proposed study will evaluate the effectiveness of an integrated group postpartum and well-child care model, compared to individual (usual) postnatal and well-child care, on maternal and child health outcomes. Results will provide clinical evidence for improved maternal and infant health care in the first year postpartum. The study will inform and provide lessons learned to advance maternal and infant health service delivery models in low resource settings.

Read the detailed description

A cluster randomized controlled trial design with mixed methods will be used to determine the impact and comparative effectiveness of group versus usual individual care with postpartum women and the women's infants in 16 clinics across Zomba District, Malawi. Data is collected at baseline, 6- and 12-months. Women are nested within the postpartum/well-child care group for the intervention. In the control arm, dyads will be grouped based on order of entry within each site. The first 10 dyads will form "group" 1, the second 10 dyads "group" 2, etc. The investigators will also explore the health and health-related social needs that arise in the 12 months after birth for both women and the women's infants through in-depth interviews as well as implementation barriers and facilitators for group postpartum and well-child care.

02

Conditions studied

  • Postpartum Health
  • Infant Health
03

Who can participate

Ages eligible
1 Week to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Aims 1\&2:

  • Women presenting for their 1-week postnatal care visit with their infant at a study site clinic.
  • Over age 15.
  • One infant is less than 4 weeks old.
  • Able to speak and understand Chichewa.
  • Adolescents 15-17 must bring parent/guardian for consent/assent. Infants included as part of mother-infant dyad.

Aim 3:

  • Midwife or HSA serving as group care co-facilitator or key stakeholders in MoH/Zomba District/clinical administration
  • Able to speak Chichewa and/or English.

Exclusion criteria

Exclusion Criteria:

Aim 1\&2

  • Under age 15.
  • Serious physical or mental illness or marked cognitive impairment preventing informed consent.
  • Inability to participate in full intervention
  • Multiple infants (e.g. twins, triplets)

Aim 3

-Serious physical or mental illness or marked cognitive impairment preventing informed consent.

04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,125 participants (estimated)

Study arms

  • Experimental
    Group Care

    Behavioral: Group Care

  • No intervention
    Usual care

Interventions

  • BehavioralGroup Care

    Group care in the postpartum period brings the same group of 8-10 women and their infants, born within one month of one another, together for one year of integrated healthcare for the dyad. Sessions are co-facilitated by a midwife and HSA. Each session is 120 minutes: first 30-45 minutes consist of self-assessments (measuring infant's weight/length, taking own vital signs) and standard health assessments by a clinician; health concerns are identified/managed and referrals made if needed. Followed by 75-90 minutes of interactive health promotion, skills-building, and support activities. 6-visit model aligned with Malawian vaccine schedule: 6 weeks, 10 weeks, 14 weeks, 6 months, 9 months, and 12 months.

05

What researchers measure

Primary outcomes

  1. Postpartum depression score as measured by the Edinburgh Postnatal Depression Scale (EPDS)

    The EPDS is a 10-item self-report scale with scores ranging from 0-30; higher scores indicate more depressive symptoms.

    Time frame: baseline, 6 months, and 12 months postpartum

  2. Infant immunization completion rate per national immunization schedule

    Time frame: 6 months, and 12 months after birth

Secondary outcomes

  1. Number of participants using a family planning method

    Time frame: baseline, 6 months and 12 months postpartum

  2. Number of Participants who recall postnatal care content as measured by structured survey

    Time frame: 6 and 12 months postpartum

  3. Self-reported peer connectedness as measured by study survey

    Peer connectedness assessed via a 14-item survey. Total score range: 0-56. Higher scores indicate greater peer connectedness.

    Time frame: 6 and 12 months postpartum

  4. Breastfeeding self-efficacy as measured by the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF)

    The BSES-SF is a 14-item self-report scale with a total score range of 14-70. Higher scores indicate greater breastfeeding self-efficacy.

    Time frame: baseline, 6 months and 12 months postpartum

  5. Number of Participants Exclusively breastfeeding at 6 months after birth

    Time frame: 6 months postpartum

  6. Partner communication as measured by relationship quality survey

    2-item survey with total score range 0-2. Higher scores indicate higher relationship quality.

    Time frame: baseline, 6 months, and 12 months postpartum

  7. Maternal nutrition as measured by dietary diversity survey

    Dietary diversity assessed via 6-item 24-hour recall with a total score range of 0-6. Higher scores indicate greater dietary diversity.

    Time frame: baseline, 6 months, and 12 months postpartum

  8. Maternal anemia - hemoglobin level measured by point-of-care bloodspot test

    Time frame: baseline and 12 months postpartum

  9. Hypertension as measured by blood pressure assessment

    Hypertension assessed by systolic and diastolic blood pressure measurement in mmHg. Hypertension defined as systolic ≥140 mmHg and/or diastolic ≥90 mmHg per WHO guidelines.

    Time frame: baseline, 6 months, and 12 months postpartum

  10. Postpartum anxiety as measured by the Generalized Anxiety Disorder 7-item Scale (GAD-7)

    Anxiety symptoms assessed using the GAD-7, a 7-item self-report scale with a total score range of 0-21. Higher scores indicate greater anxiety.

    Time frame: baseline, 6 months, and 12 months postpartum

  11. Maternal mortality as measured by clinic reporting

    Time frame: 6 months and 12 months postpartum

  12. Infant growth as measured by weight-for-age per growth standards

    Time frame: baseline, 6 months, and 12 months after birth

  13. Infant growth as measured by length-for-age per growth standards

    Time frame: baseline, 6 months, 12 months after birth

  14. Infant nutritional status as measured by mid-upper arm circumference (MUAC)

    Time frame: 6 months and 12 months after birth

  15. Infant anemia as measured by point-of-care hemoglobin bloodspot test

    Time frame: 12 months after birth

  16. Child development as measured by the Malawi Developmental Assessment Tool (MDAT)

    Child development assessed using the MDAT, a tool measuring four domains: gross motor, fine motor, language, and social development. Each domain is scored 0-34 based on passed items. Total score range: 0-136. Higher scores indicate more advanced development.

    Time frame: 6 months and 12 months after birth

  17. Infant mortality as measured by clinic reporting and parent's self-report

    Time frame: 6 months and 12 months after birth

06

Study locations

8 of 16 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07414901
Lead sponsor
Johns Hopkins University
Collaborators
National Institute of Nursing Research (NINR), University of Michigan, Kamuzu University of Health Sciences
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 30, 2026
Primary completion
Nov 30, 2029 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Jul 9, 2026

Study contacts

Ashley Gresh
Contact
ashley.gresh@jhu.edu
603-831-3942
Ellen Chirwa
Contact
embweza@kuhes.ac.mw
+265888940513
Ashley Gresh
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion